Piper Jaffray adds Eagle Pharmaceuticals Inc (EGRX) to its portfolio

Eagle Pharmaceuticals Inc (EGRX) : Piper Jaffray added new position in Eagle Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 100 shares of Eagle Pharmaceuticals Inc which is valued at $8,312 , the company said in a statement filed on Nov 14, 2016 with the SEC.Eagle Pharmaceuticals Inc makes up approximately 0.33% of Piper Jaffray’s portfolio.

Other Hedge Funds, Including , Paulson sold out all of its stake in EGRX during the most recent quarter. The investment firm sold 21,000 shares of EGRX which is valued $1,745,520.Rhumbline Advisers boosted its stake in EGRX in the latest quarter, The investment management firm added 2,418 additional shares and now holds a total of 11,713 shares of Eagle Pharmaceuticals Inc which is valued at $873,673. Victory Capital Management Inc added EGRX to its portfolio by purchasing 690,260 company shares during the most recent quarter which is valued at $49,077,486. Eagle Pharmaceuticals Inc makes up approx 0.15% of Victory Capital Management Inc’s portfolio.American Century Companies Inc reduced its stake in EGRX by selling 87,476 shares or 76.13% in the most recent quarter. The Hedge Fund company now holds 27,425 shares of EGRX which is valued at $1,867,643.

Eagle Pharmaceuticals Inc opened for trading at $78.3 and hit $79.3 on the upside on Monday, eventually ending the session at $78.72, with a gain of 0.69% or 0.54 points. The heightened volatility saw the trading volume jump to 3,76,216 shares. Company has a market cap of $1,218 M.

On the company’s financial health, Eagle Pharmaceuticals Inc reported $0.73 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Nov 9, 2016. Analyst had a consensus of $0.66. The company had revenue of $37.80 million for the quarter, compared to analysts expectations of $38.57 million. The company’s revenue was up 563.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.65 EPS.

Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Mizuho Downgraded Eagle Pharmaceuticals Inc on Nov 16, 2016 to ” Neutral”, Price Target of the shares are set at $78.Company shares were Upgraded by Mizuho on Nov 3, 2016 to ” Buy”, Firm has raised the Price Target to $ 78 from a previous price target of $62 .Company shares were Reiterated by RBC Capital Mkts on Nov 3, 2016 to “Outperform”, Firm has raised the Price Target to $ 93 from a previous price target of $80 .

Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.

Leave a Reply

Eagle Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eagle Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.